Delivery Order SPE2DR25D1053-SPE2DR26FT119
Award Date 10/20/25
Potential Completion Date 11/10/25
Potential Value $26K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used...
- The Defense Logistics Agency awarded a $8,122.48 delivery order to AmerisourceBergen Drug Corp for 7 tablets of Ibrance 100 mg on June 5, 2025, with completion scheduled for June 27, 2025. This competitively awarded, firm fixed-price order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a brand-name oncology medication used in cancer treatment, reflecting the pharmaceutical distribution services that...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) under a firm fixed-price contract valued at $8,122.48, with an ultimate completion date of October 21, 2025. This non-competitive delivery order was issued on September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency awarded a delivery order valued at $16,240.56 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count units) on July 16, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ibrance is an oncology medication used in cancer treatment, reflecting the critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) valued at $8,123.96 with an ultimate completion date of September 26, 2025. This contract represents a firm fixed-price delivery order under a non-set-aside competitive procurement, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ibrance is a prescription pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on June 2, 2025, with an ultimate completion date of June 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania location. Ibrance is a prescription oncology medication used in breast cancer treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count units) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded and scheduled for completion by September 16, 2025. The contract was issued on August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count unit) on July 22, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the...